ID   SW579
AC   CVCL_3603
SY   SW-579; SW 579
DR   CLO; CLO_0009220
DR   ArrayExpress; E-MTAB-2770
DR   ATCC; HTB-107
DR   BCRC; 60412
DR   BioSample; SAMN10988339
DR   cancercelllines; CVCL_3603
DR   CCRID; 1101HUM-PUMC000264
DR   CCRID; 3101HUMTCHu125
DR   Cell_Model_Passport; SIDM01167
DR   CLS; 300346
DR   Cosmic; 1005454
DR   Cosmic; 1006467
DR   Cosmic; 1017791
DR   Cosmic; 1041672
DR   Cosmic; 1094773
DR   Cosmic; 1339924
DR   DepMap; ACH-000163
DR   GEO; GSM887676
DR   GEO; GSM888768
DR   GEO; GSM1374931
DR   GEO; GSM1374932
DR   IARC_TP53; 1308
DR   IGRhCellID; SW579
DR   IZSLER; BS TCL 121
DR   KCB; KCB 2013004YJ
DR   LiGeA; CCLE_771
DR   PharmacoDB; SW579_1540_2019
DR   Progenetix; CVCL_3603
DR   Wikidata; Q54971179
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=1516062;
RX   PubMed=3518877;
RX   PubMed=6220172;
RX   PubMed=22460905;
RX   PubMed=26589293;
RX   PubMed=29066502;
RX   PubMed=30894373;
RX   PubMed=31068700;
RX   PubMed=31443247;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: KuDOS 95 cell line panel.
CC   From: Scott and White Clinic; Temple; USA.
CC   Population: Caucasian.
CC   HLA typing: A*02:01,02:01; B*07:43,51:01; C*15:02,15:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=31068700).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Ile255Ser (c.764T>G); ClinVar=VCV000376622; Zygosity=Homozygous (PubMed=1516062; DepMap=ACH-000163).
CC   Omics: Genomics; Mitochondrial genome sequencing.
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Genome ancestry: African=0.11%; Native American=1.95%; East Asian, North=0.43%; East Asian, South=0%; South Asian=0.91%; European, North=63.94%; European, South=32.66% (PubMed=30894373).
CC   Derived from site: In situ; Thyroid gland; UBERON=UBERON_0002046.
ST   Source(s): ATCC=HTB-107; CCRID; CLS=300346; IZSLER=BS TCL 121
ST   Amelogenin: X
ST   CSF1PO: 13
ST   D13S317: 13
ST   D16S539: 11
ST   D18S51: 15,17,18
ST   D19S433: 13,14
ST   D21S11: 29,31
ST   D2S1338: 17,18
ST   D3S1358: 15,18
ST   D5S818: 11
ST   D7S820: 8,9
ST   D8S1179: 11,13
ST   FGA: 21,24
ST   Penta D: 9,12
ST   Penta E: 11,12
ST   TH01: 8,9.3
ST   TPOX: 8,10
ST   vWA: 14,18
DI   NCIt; C46008; Thyroid gland squamous cell carcinoma
DI   ORDO; Orphanet_100088; Thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   59Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 36
//
RX   DOI=10.1016/B978-0-12-333530-2.50007-1;
RA   Carey T.E.;
RT   "Head and neck tumor cell lines.";
RL   (In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.79-120; Academic Press; New York; USA (1994).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=1516062;
RA   Yoshimoto K., Iwahana H., Fukuda A., Sano T., Saito S., Itakura M.;
RT   "Role of p53 mutations in endocrine tumorigenesis: mutation detection
RT   by polymerase chain reaction-single strand conformation
RT   polymorphism.";
RL   Cancer Res. 52:5061-5064(1992).
//
RX   PubMed=3518877; DOI=10.3109/07357908609038260;
RA   Fogh J.;
RT   "Human tumor lines for cancer research.";
RL   Cancer Invest. 4:157-184(1986).
//
RX   PubMed=6220172;
RA   Dracopoli N.C., Fogh J.;
RT   "Polymorphic enzyme analysis of cultured human tumor cell lines.";
RL   J. Natl. Cancer Inst. 70:469-476(1983).
//
RX   PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027;
RA   Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A.,
RA   Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A.,
RA   Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J.,
RA   Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E.,
RA   Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J.,
RA   Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C.,
RA   Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C.,
RA   Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P.,
RA   Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L.,
RA   Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R.,
RA   Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.;
RT   "The Cancer Cell Line Encyclopedia enables predictive modelling of
RT   anticancer drug sensitivity.";
RL   Nature 483:603-607(2012).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5; PMCID=PMC4653878;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29066502; DOI=10.1530/ERC-17-0288;
RA   Corver W.E., Demmers J., Oosting J., Sahraeian S., Boot A., Ruano D.,
RA   van Wezel T., Morreau H.;
RT   "ROS-induced near-homozygous genomes in thyroid cancer.";
RL   Endocr. Relat. Cancer 25:83-97(2018).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=31068700; DOI=10.1038/s41586-019-1186-3; PMCID=PMC6697103;
RA   Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C.,
RA   McDonald E.R. 3rd, Barretina J.G., Gelfand E.T., Bielski C.M., Li H.-X.,
RA   Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F.,
RA   Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R.,
RA   Lu Y.-L., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C.,
RA   Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A.,
RA   Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D.,
RA   Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L.,
RA   Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A.,
RA   Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D.,
RA   Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M.,
RA   Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R.,
RA   Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A.,
RA   Sellers W.R.;
RT   "Next-generation characterization of the Cancer Cell Line
RT   Encyclopedia.";
RL   Nature 569:503-508(2019).
//
RX   PubMed=31443247; DOI=10.3390/cancers11081185; PMCID=PMC6721552;
RA   Aydemirli M.D., Corver W.E., Beuk R., Roepman P.,
RA   Solleveld-Westerink N., van Wezel T., Kapiteijn E.H.W., Morreau H.;
RT   "Targeted treatment options of recurrent radioactive iodine refractory
RT   Hurthle cell cancer.";
RL   Cancers (Basel) 11:1185.1-1185.16(2019).
//